Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3,597 patients

Journal of Clinical Oncology

Volumn 21, Issue 24, 2003, Pages 4615-4626

  Glasmacher, Axel ^a   Prentice, Archibald ^a   Gorschlüter, Marcus ^a   Engelhart, Steffen ^a   Hahn, Corinna ^a   Djulbegovic, Benjamin ^a   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; ANTIFUNGAL AGENT;

ARTICLE; ASPERGILLOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; META ANALYSIS; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; BLOOD DISEASE; CHI SQUARE DISTRIBUTION; MYCOSIS;

ANTIFUNGAL AGENTS; CHI-SQUARE DISTRIBUTION; HEMATOLOGIC NEOPLASMS; HUMANS; ITRACONAZOLE; MYCOSES; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS;

EID: 1542438612     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.052     Document Type: Article

References (44)

1. Prentice HG, Kibbler CC, Prentice AG: Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 110:273-284,2000
2. Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 32:358-366, 2001
3. Viscoli C, Girmenia C, Marinus A, et al: Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28:1071-1079, 1999
4. Mair KA, Seidel K, White TC, et al: Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 181:309-316, 2000
5. Kanda Y, Yamamoto R, Chizuka A, et al: Prophylactic action of oral fluconazole against fungal infection in neutropenic patients: A meta-analysis of 16 randomized, controlled trials. Cancer 89:1611-1625, 2000
6. Bow EJ, Laverdiere M, Lussier N, et al: Antifungal prophylaxis for severely neutropenic chemotherapy recipients: A meta analysis of randomized-controlled clinical trials. Cancer 94:3230-3246, 2002
7. Egger M, Smith GD, O'Rourke K: Rationale, potentials and promise of systematic reviews, in Egger M, Smith GD, Altman DG (eds): Systematic reviews in health care-Meta-analysis in context. London, United Kingdom, BMJ Publishing Group, 2001, pp 3-19
8. Lass-Flörl C, Gunsilius E, Gastl G, et al: Fungal colonization in neutropenic patients: A randomized study comparing itraconazole solution and amphotericin B solution. Ann Hematol 82:565-569, 2003
9. Winston DJ, Maziarz RT, Chandrasekar PH, et al: Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: A multicenter, randomized trial. Ann Intern Med 138:705-713, 2003
10. Marr KA, Crippa F, Leisenring W, et al: Itraconazole versus fluconazole for prevention of fungal infections in allogeneic HSCT recipients: Results of a randomized trial. Blood 100:215a, 2002 (suppl 1, part 1; abstr)
11. Ascioglu S, Rex JH, de Pauw B, et al: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 34:7-14, 2002
12. Vreugdenhil G, Van Dijke BJ, Donnelly JP, et al: Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy: A double blind, placebo controlled study. Leuk Lymphoma 11:353-358, 1993
13. Harousseau JL, Dekker A, Stamatoullas-Bastard A, et al: Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematologic malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 44:1887-1893, 2000
14. Morgenstern GR, Prentice AG, Prentice HG, et al: A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies: U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 105:901-911, 1999
15. Boogaerts M, Maertens J, van Hoof A, et al: Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 48:97-103, 2001
16. Menichetti F, Del Favero A, Martino P, et al: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 28:250-255, 1999
17. Nucci M, Biasoli I, Akiti T, et al: A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 30:300-305, 2000
18. Huijgens PC, Simoons-Smit AM, van Loenen AC, et al: Fluconazole versus itraconazole for the prevention of fungal infections in haematooncology. J Clin Pathol 52:376-380, 1999
19. Grant SM, Clissod SP: Itraconazole: A review of its pharmacodynamic and pharmacokinetik properties, and therapeutic use in superficial and systemic mycoses. Drugs 37:310-344, 1989
20. de Beule K: Itraconazole: Pharmacology, clinical experience and future development. Int J Antimicrob Agents 6:175-181, 1996
21. Heykants J, van Peer A, van de Velde V, et al: The clinical pharmacokinetics of itraconazole: An overview. Mycoses 32:67-87, 1989 (suppl 1)
22. Glasmacher A, Hahn C, Molitor E, et al: Itraconazole trough levels in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-cyclodextrin oral solution or coated-pellet capsules. Mycoses 42:591-600, 1999
23. Clarke M, Oxman AD: Cochrane Reviewers Handbook 4.1.5. Oxford, United Kingdom, Update Software, 2002, pp 1-165
24. Moher D, Cook DJ, Eastwood S, et al: Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement-Quality of Reporting of Meta-analyses. Lancet 354:1896-1900, 1999
25. Annaloro C, Oriani A, Tagliaferri E, et al: Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica 80:512-517, 1995
26. Kaptan K, Ural AU, Cetin T, et al: Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia. J Infect Chemother 9:40-45, 2003
27. Gotzsche PC, Johansen HK: Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 314:1238-1244, 1997
28. Gotzsche PC, Johansen HK: Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev CD000026, 2002
29. Berenguer J, Ali NM, Allende CM, et al: Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother 38:1303-1308, 1994
30. Manavathu EK, Cutright JL, Chandrasekar PH: Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 42:3018-3021, 1998
31. Odds FC, Van Gerven F, Espinel Ingroff A, et al: Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infections models. Antimicrob Agents Chemother 42:282-288, 1998
32. Rex JH, Pfaller MA, Galgiani JN, et al: Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, Itraconazole, and Candida infections: Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 24:235-247, 1997
33. Glasmacher A, Hahn C, Leutner C, et al: Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 42:443-451, 1999
34. Groll AH, Wood L, Roden M, et al: Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 46:2554-2563, 2002
35. Glasmacher A, Hahn C, Molitor E, et al: Minimal effective trough concentrations for antifungal prophylaxis with Itraconazole: a case-control study. Proc Intersc Conf Antimicrob Agents Chemother 40:M-890, 2002 (abstr M-890)
36. Bradford CR, Prentice AG, Warnock DW, et al: Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. J Antimicrob Chemother 28:555-560, 1991
37. Prentice AG, Warnock DW, Johnson SA, et al: Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 34:247-252, 1994
38. Prentice AG, Warnock DW, Johnson SA, et al: Multiple dose pharmacokinetics of an oral solution of Itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J Antimicrob Chemother 36:657-663, 1995
39. Boogaerts MA, Verhoef GE, Zachee P, et al: Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 32:103-108, 1989
40. Flynn TN, Kelsey SM, Hazel DL, et al: Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy: Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK. Pharmacoeconomics 16:543-550, 1999
41. Wilson LS, Reyes CM, Stolpman M, et al: The direct cost and incidence of systemic fungal infections. Value Health 5:26-34, 2002
42. Marr KA, Seidel K, Slavin MA, et al: Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial. Blood 96:2055-2061, 2000
43. Jantunen E, Ruutu P, Niskanen L, et al: Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 19:801-808, 1997
44. Wald A, Leisenring W, van Burik JA, et al: Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175:1459-1466, 1997